Merck & Co (NY:MRK)

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Topics Economy

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

Via The Motley Fool

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

Topics Economy Initial Public Offering Intellectual Property

January 07, 2026

From Merck & Co., Inc.

Merck to Complete Acquisition of Cidara Therapeutics

January 07, 2026

From Merck Sharp & Dohme

Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

January 07, 2026

From Merck & Co., Inc.

As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...

The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026

January 06, 2026

US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK ↗

Topics Artificial Intelligence Economy Government

January 06, 2026

In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every...

Via Benzinga

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

January 05, 2026

The highest-yielding stocks in the Dow are Verizon, Chevron, and Merck, but should you buy any of them?

Via The Motley Fool

Topics Stocks

U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗

January 05, 2026

Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.

Via Stocktwits

Topics Government

Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Merck & Co., Inc.

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations

Topics Economy Intellectual Property World Trade

January 02, 2026

As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional...

As the financial markets cross the threshold into 2026, investors find themselves navigating a complex landscape defined by "tariff-driven" volatility and a shift toward earnings-justified valuations....

Topics Artificial Intelligence Economy

Generating Yield in a Sideways Market: The Strategic Rise of Dow Jones Covered Call ETFs

January 01, 2026

Pfizer’s Dividend Trap or Deep Value? Analyzing the Pharma Giant as Shares Languish Below $30

Topics ETFs Economy Regulatory Compliance

January 01, 2026

As the calendar turns to January 1, 2026, Pfizer Inc. (NYSE: PFE) finds itself in a position that would have been unthinkable during the height of the pandemic. Once the darling of the pharmaceutical...

The Metabolic Squeeze: Big Pharma’s 2025 Defined by $1 Trillion Valuations and Regulatory Reckonings

Topics Intellectual Property

December 31, 2025

As 2025 draws to a close, the pharmaceutical industry stands at a historic crossroads. The year was defined by a widening chasm between the "metabolic haves"—those profiting from the global obesity...

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the...

Topics Economy Intellectual Property Law Enforcement

Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026

December 31, 2025

As 2025 draws to a close, the global financial landscape is bracing for what analysts are calling an "Innovation Supercycle" in the mergers and acquisitions (M&A) market. With interest rates finally...

Topics Artificial Intelligence ETFs Economy

The Great Consolidation: Why 2026 is Set to Become the Year of the Mega-Deal

December 30, 2025

As the sun sets on 2025, investors are increasingly pivoting toward the pharmaceutical sector, seeking a "defensive income fortress" to weather potential macroeconomic volatility in 2026. The...

Topics Artificial Intelligence Economy Intellectual Property

The 2026 Income Fortress: Why Big Pharma is the Defensive Play of the New Year

December 30, 2025

Wondering what's happening in today's after-hours session with S&P500 stocks? Stay tuned for the latest updates on movers and shakers.

Topics Artificial Intelligence Economy Intellectual Property

Top gainers and losers in the S&P500 index during Monday's after-hours session. ↗

December 29, 2025

Via Chartmill

The Price of Prosperity: Navigating the S&P 500’s Historic Valuation Peak as 2026 Dawns

December 29, 2025

As the final trading days of 2025 draw to a close, the financial world finds itself standing on a high-altitude plateau that few predicted and many fear. The S&P 500 (INDEXSP: .INX) enters 2026 trading...

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.

Topics Artificial Intelligence Bonds Earnings

3 Drug Stocks to Buy at a Discount ↗

December 27, 2025

Via The Motley Fool

Topics Intellectual Property

The Dynavax Turnaround: From Clinical Setbacks to a $2.2 Billion Exit

December 26, 2025

As of December 26, 2025, the biotechnology landscape is processing one of the most significant mid-cap acquisitions of the year. Dynavax Technologies Corporation (NASDAQ: DVAX) has transitioned from a...

Merck exemplifies quality investing with high ROIC, strong cash flow, and a solid balance sheet, making it a durable long-term healthcare investment candidate.

Merck & Co. Inc. (NYSE:MRK) Emerges as a Top Quality Investing Candidate ↗

December 26, 2025

Via Chartmill

Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom

December 25, 2025

NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of...

As investors close the books on 2025, a year defined by the continued—yet tiring—dominance of artificial intelligence and mega-cap technology, the financial community is turning its gaze toward a...

Topics Economy Intellectual Property

Barking Back: Why the 'Dogs of the Dow' 4-Stock Play is the Contrarian Bet for 2026

December 25, 2025

The Great Vaccine Consolidation: Sanofi’s $2.2 Billion Strategic Bet on Dynavax Technologies

Topics Artificial Intelligence Economy Intellectual Property

December 25, 2025

Dateline: December 25, 2025 Introduction In a move that has sent shockwaves through the biotechnology and pharmaceutical sectors on this Christmas Day, the global vaccine landscape has been...

As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:...

Topics Economy Intellectual Property

The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax

December 25, 2025

Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025

Topics Artificial Intelligence Economy Intellectual Property

December 24, 2025

As the curtain closes on 2025, the healthcare sector has emerged as a landscape of stark contrasts. While traditional pharmaceutical giants have grappled with the implementation of the Medicare Part D...